{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:35:22Z","timestamp":1794105322425,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY022349"],"award-info":[{"award-number":["R01 EY022349"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY017427"],"award-info":[{"award-number":["R01 EY017427"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U24 EY029893"],"award-info":[{"award-number":["U24 EY029893"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["U24 EY029903"],"award-info":[{"award-number":["U24 EY029903"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30 EY008126"],"award-info":[{"award-number":["P30 EY008126"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-2-0055"],"award-info":[{"award-number":["W81XWH-17-2-0055"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glaucoma, the second leading cause of irreversible blindness worldwide, is associated with age and sensitivity to intraocular pressure (IOP). We have shown that elevated IOP causes an early increase in levels of reactive oxygen species (ROS) in the microbead occlusion mouse model. We also detected an endogenous antioxidant response mediated by Nuclear factor erythroid 2-Related Factor 2 (NRF2), a transcription factor that binds to the antioxidant response element (ARE) and increases transcription of antioxidant genes. Our previous studies show that inhibiting this pathway results in earlier and greater glaucoma pathology. In this study, we sought to determine if this endogenous antioxidant response is driven by the retinal ganglion cells (RGCs) or glial cells. We used Nrf2\n                    <jats:sup>fl\/fl<\/jats:sup>\n                    mice and cell-type specific adeno-associated viruses (AAVs) expressing Cre to alter Nrf2 levels in either the RGCs or glial cells. Then, we quantified the endogenous antioxidant response, visual function and optic nerve histology after IOP elevation. We found that knock-down of Nrf2 in either cell type blunts the antioxidant response and results in earlier pathology and vision loss. Further, we show that delivery of Nrf2 to the RGCs is sufficient to provide neuroprotection. In summary, both the RGCs and glial cells contribute to the antioxidant response, but treatment of the RGCs alone with increased Nrf2 is sufficient to delay onset of vision loss and axon degeneration in this induced model of glaucoma.\n                  <\/jats:p>","DOI":"10.1186\/s40478-023-01663-1","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T05:20:50Z","timestamp":1698124850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["NRF2\/ARE mediated antioxidant response to glaucoma: role of glia and retinal ganglion cells"],"prefix":"10.1186","volume":"11","author":[{"given":"Sarah","family":"Naguib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon R.","family":"Backstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Artis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer A.","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Calkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-8723","authenticated-orcid":false,"given":"Tonia S.","family":"Rex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"issue":"6","key":"1663_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.preteyeres.2012.07.001","volume":"31","author":"DJ Calkins","year":"2012","unstructured":"Calkins DJ (2012) Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog Retin Eye Res 31(6):702\u2013719. https:\/\/doi.org\/10.1016\/j.preteyeres.2012.07.001","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"1663_CR2","doi-asserted-by":"publisher","first-page":"1000e7","DOI":"10.1016\/j.amjmed.2016.03.038","volume":"129","author":"A Greco","year":"2016","unstructured":"Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, de Vincentiis M (2016) Emerging concepts in Glaucoma and review of the literature. Am J Med 129(9):1000e7\u20131000e13. https:\/\/doi.org\/10.1016\/j.amjmed.2016.03.038","journal-title":"Am J Med"},{"issue":"5","key":"1663_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41433-018-0042-2","volume":"32","author":"HE Killer","year":"2018","unstructured":"Killer HE, Pircher A (2018) Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis. Eye 32(5):924\u2013930. https:\/\/doi.org\/10.1038\/s41433-018-0042-2","journal-title":"Eye"},{"issue":"18","key":"1663_CR4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA (2014) The pathophysiology and treatment of glaucoma: a review. JAMA 311(18):1901\u20131911. https:\/\/doi.org\/10.1001\/jama.2014.3192","journal-title":"JAMA"},{"issue":"11","key":"1663_CR5","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11):2081\u20132090. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013","journal-title":"Ophthalmology"},{"issue":"3","key":"1663_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.freeradbiomed.2005.03.025","volume":"39","author":"ML Ko","year":"2005","unstructured":"Ko ML, Peng PH, Ma MC, Ritch R, Chen CF (2005) Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med 39(3):365\u2013373. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2005.03.025","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"1663_CR7","doi-asserted-by":"publisher","first-page":"e65389","DOI":"10.1371\/journal.pone.0065389","volume":"8","author":"DM Inman","year":"2013","unstructured":"Inman DM, Lambert WS, Calkins DJ, Horner PJ (2013) \u03b1-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS ONE 8(6):e65389. https:\/\/doi.org\/10.1371\/journal.pone.0065389","journal-title":"PLoS ONE"},{"key":"1663_CR8","doi-asserted-by":"publisher","first-page":"101883","DOI":"10.1016\/j.redox.2021.101883","volume":"42","author":"S Naguib","year":"2021","unstructured":"Naguib S, Backstrom JR, Gil M, Calkins DJ, Rex TS (2021) Retinal oxidative stress activates the NRF2\/ARE pathway: an early endogenous protective response to ocular hypertension. Redox Biol 42:101883. https:\/\/doi.org\/10.1016\/j.redox.2021.101883","journal-title":"Redox Biol"},{"issue":"17","key":"1663_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1089\/ars.2017.7342","volume":"29","author":"C Tonelli","year":"2018","unstructured":"Tonelli C, Chio IIC, Tuveson DA (2018) Transcriptional regulation by Nrf2. Antioxid Redox Signal 29(17):1727\u20131745. https:\/\/doi.org\/10.1089\/ars.2017.7342","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"1663_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3892\/etm.2017.4543","volume":"14","author":"J Cheng","year":"2017","unstructured":"Cheng J, Liang J, Qi J (2017) Role of nuclear factor (erythroid-derived 2)-like 2 in the age-resistant properties of the glaucoma trabecular meshwork. Experimental and Therapeutic Medicine 14(1):791\u2013796. https:\/\/doi.org\/10.3892\/etm.2017.4543","journal-title":"Experimental and Therapeutic Medicine"},{"key":"1663_CR11","doi-asserted-by":"publisher","unstructured":"Batliwala S, Xavier C, Liu Y, Wu H, Pang IH (2017) Involvement of Nrf2 in Ocular Diseases. Oxidative medicine and cellular longevity, 2017, 1703810. https:\/\/doi.org\/10.1155\/2017\/1703810","DOI":"10.1155\/2017\/1703810"},{"key":"1663_CR12","doi-asserted-by":"publisher","unstructured":"Nakagami Y (2016) Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases. Oxidative medicine and cellular longevity, 2016, 7469326. https:\/\/doi.org\/10.1155\/2016\/7469326","DOI":"10.1155\/2016\/7469326"},{"issue":"2","key":"1663_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jnc.13064","volume":"133","author":"Z Xu","year":"2015","unstructured":"Xu Z, Cho H, Hartsock MJ, Mitchell KL, Gong J, Wu L, Wei Y, Wang S, Thimmulappa RK, Sporn MB, Biswal S, Welsbie DS, Duh EJ (2015) Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusion. J Neurochem 133(2):233\u2013241. https:\/\/doi.org\/10.1111\/jnc.13064","journal-title":"J Neurochem"},{"issue":"9","key":"1663_CR14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.7150\/ijbs.25996","volume":"14","author":"XF Liu","year":"2018","unstructured":"Liu XF, Zhou DD, Xie T, Hao JL, Malik TH, Lu CB, Qi J, Pant OP, Lu CW (2018) The Nrf2 Signaling in Retinal Ganglion cells under oxidative stress in ocular neurodegenerative Diseases. Int J Biol Sci 14(9):1090\u20131098. https:\/\/doi.org\/10.7150\/ijbs.25996","journal-title":"Int J Biol Sci"},{"issue":"5","key":"1663_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/jnc.12325","volume":"127","author":"N Himori","year":"2013","unstructured":"Himori N, Yamamoto K, Maruyama K, Ryu M, Taguchi K, Yamamoto M, Nakazawa T (2013) Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death. J Neurochem 127(5):669\u2013680. https:\/\/doi.org\/10.1111\/jnc.12325","journal-title":"J Neurochem"},{"issue":"1","key":"1663_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.redox.2012.10.001","volume":"1","author":"E Kansanen","year":"2013","unstructured":"Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL (2013) The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1(1):45\u201349. https:\/\/doi.org\/10.1016\/j.redox.2012.10.001","journal-title":"Redox Biol"},{"key":"1663_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.redox.2018.05.002","volume":"17","author":"A Raghunath","year":"2018","unstructured":"Raghunath A, Sundarraj K, Nagarajan R, Arfuso F, Bian J, Kumar AP, Sethi G, Perumal E (2018) Antioxidant response elements: Discovery, classes, regulation and potential applications. Redox Biol 17:297\u2013314. https:\/\/doi.org\/10.1016\/j.redox.2018.05.002","journal-title":"Redox Biol"},{"issue":"20","key":"1663_CR18","doi-asserted-by":"publisher","first-page":"15466","DOI":"10.1074\/jbc.M000361200","volume":"275","author":"T Nguyen","year":"2000","unstructured":"Nguyen T, Huang HC, Pickett CB (2000) Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK. J Biol Chem 275(20):15466\u201315473. https:\/\/doi.org\/10.1074\/jbc.M000361200","journal-title":"J Biol Chem"},{"issue":"3","key":"1663_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/antiox12030556","volume":"12","author":"S Naguib","year":"2023","unstructured":"Naguib S, DeJulius CR, Backstrom JR, Haider AA, Ang JM, Boal AM, Calkins DJ, Duvall CL, Rex TS (2023) Intraocular sustained release of EPO-R76E mitigates Glaucoma pathogenesis by activating the NRF2\/ARE pathway. Antioxid (Basel Switzerland) 12(3):556. https:\/\/doi.org\/10.3390\/antiox12030556","journal-title":"Antioxid (Basel Switzerland)"},{"key":"1663_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.omtm.2020.09.001","volume":"19","author":"JR Backstrom","year":"2020","unstructured":"Backstrom JR, Sheng J, Wang MC, Bernardo-Col\u00f3n A, Rex TS (2020) Optimization of S. aureus dCas9 and CRISPRi elements for a single Adeno-Associated Virus that targets an endogenous gene. Mol Therapy Methods Clin Dev 19:139\u2013148. https:\/\/doi.org\/10.1016\/j.omtm.2020.09.001","journal-title":"Mol Therapy Methods Clin Dev"},{"key":"1663_CR21","doi-asserted-by":"crossref","unstructured":"Portales-Casamar, E., Swanson, D. J., Liu, L., de Leeuw, C. N., Banks, K. G., Ho Sui,S. J., Fulton, D. L., Ali, J., Amirabbasi, M., Arenillas, D. J., Babyak, N., Black,S. F., Bonaguro, R. J., Brauer, E., Candido, T. R., Castellarin, M., Chen, J., Chen,Y., Cheng, J. C., Chopra, V., \u2026 Simpson, E. M. (2010). A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proceedings of the National Academy of Sciences of the United States of America, 107(38), 16589\u201316594. https:\/\/doi.org\/10.1073\/pnas.1009158107","DOI":"10.1073\/pnas.1009158107"},{"issue":"20","key":"1663_CR22","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1523\/JNEUROSCI.0102-20.2020","volume":"40","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhuang P, Huang H, Li L, Liu L, Webber HC, Dalal R, Siew L, Fligor CM, Chang KC, Nahmou M, Kreymerman A, Sun Y, Meyer JS, Goldberg JL, Hu Y (2020) Mouse \u03b3-Synuclein promoter-mediated gene expression and editing in mammalian retinal ganglion cells. J Neuroscience: Official J Soc Neurosci 40(20):3896\u20133914. https:\/\/doi.org\/10.1523\/JNEUROSCI.0102-20.2020","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"issue":"1","key":"1663_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1167\/iovs.09-3947","volume":"51","author":"RM Sappington","year":"2010","unstructured":"Sappington RM, Carlson BJ, Crish SD, Calkins DJ (2010) The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Investig Ophthalmol Vis Sci 51(1):207\u2013216. https:\/\/doi.org\/10.1167\/iovs.09-3947","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1663_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4939-7407-8_3","volume":"1695","author":"DJ Calkins","year":"2018","unstructured":"Calkins DJ, Lambert WS, Formichella CR, McLaughlin WM, Sappington RM (2018) The microbead occlusion model of ocular hypertension in mice. Methods in Molecular Biology (Clifton N J) 1695:23\u201339. https:\/\/doi.org\/10.1007\/978-1-4939-7407-8_3","journal-title":"Methods in Molecular Biology (Clifton N J)"},{"issue":"2","key":"1663_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/mt.2015.198","volume":"24","author":"WS Bond","year":"2016","unstructured":"Bond WS, Hines-Beard J, GoldenMerry YL, Davis M, Farooque A, Sappington RM, Calkins DJ, Rex TS (2016) Virus-mediated EpoR76E therapy slows Optic nerve axonopathy in experimental Glaucoma. Mol Therapy: J Am Soc Gene Therapy 24(2):230\u2013239. https:\/\/doi.org\/10.1038\/mt.2015.198","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"1663_CR26","doi-asserted-by":"publisher","first-page":"108369","DOI":"10.1016\/j.exer.2020.108369","volume":"202","author":"S Naguib","year":"2021","unstructured":"Naguib S, Bernardo-Col\u00f3n A, Rex TS (2021) Intravitreal injection worsens outcomes in a mouse model of indirect traumatic optic neuropathy from closed globe injury. Exp Eye Res 202:108369. https:\/\/doi.org\/10.1016\/j.exer.2020.108369","journal-title":"Exp Eye Res"},{"key":"1663_CR27","doi-asserted-by":"publisher","unstructured":"Robledinos-Ant\u00f3n N, Fern\u00e1ndez-Gin\u00e9s R, Manda G, Cuadrado A (2019) Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative medicine and cellular longevity, 2019, 9372182. https:\/\/doi.org\/10.1155\/2019\/9372182","DOI":"10.1155\/2019\/9372182"},{"key":"1663_CR28","doi-asserted-by":"publisher","unstructured":"Pitoniak A, Bohmann D (2015) Mechanisms and functions of Nrf2 signaling in Drosophila. Free Radical Biology & Medicine 88(Pt B) 302\u2013313. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.020","DOI":"10.1016\/j.freeradbiomed.2015.06.020"},{"issue":"4","key":"1663_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","volume":"18","author":"A Cuadrado","year":"2019","unstructured":"Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT (2019) Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 18(4):295\u2013317. https:\/\/doi.org\/10.1038\/s41573-018-0008-x","journal-title":"Nat Rev Drug Discov"},{"key":"1663_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12974-016-0499-5","volume":"13","author":"J Hines-Beard","year":"2016","unstructured":"Hines-Beard J, Bond WS, Backstrom JR, Rex TS (2016) Virus-mediated EpoR76E gene therapy preserves vision in a glaucoma model by modulating neuroinflammation and decreasing oxidative stress. J Neuroinflamm 13:39. https:\/\/doi.org\/10.1186\/s12974-016-0499-5","journal-title":"J Neuroinflamm"},{"issue":"10","key":"1663_CR31","doi-asserted-by":"publisher","first-page":"e7467","DOI":"10.1371\/journal.pone.0007467","volume":"4","author":"RR Klimczak","year":"2009","unstructured":"Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV (2009) A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat M\u00fcller cells. PLoS ONE 4(10):e7467. https:\/\/doi.org\/10.1371\/journal.pone.0007467","journal-title":"PLoS ONE"},{"key":"1663_CR32","unstructured":"Rasband WS, ImageJ US National Institutes of Health, Bethesda, Maryland, USA, https:\/\/imagej.nih.gov\/ij\/, 1997\u20132018"},{"issue":"26","key":"1663_CR33","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","volume":"10","author":"A Auricchio","year":"2001","unstructured":"Auricchio A, Kobinger G, Anand V, Hildinger M, O\u2019Connor E, Maguire AM, Wilson JM, Bennett J (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10(26):3075\u20133081. https:\/\/doi.org\/10.1093\/hmg\/10.26.3075","journal-title":"Hum Mol Genet"},{"key":"1663_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.omtm.2018.11.008","volume":"13","author":"SH Lee","year":"2018","unstructured":"Lee SH, Yang JY, Madrakhimov S, Park HY, Park K, Park TK (2018) Adeno-Associated viral vector 2 and 9 transduction is enhanced in Streptozotocin-Induced Diabetic mouse retina. Mol Ther Methods Clin Dev 13:55\u201366. https:\/\/doi.org\/10.1016\/j.omtm.2018.11.008","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"1663_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41434-022-00380-z","volume":"30","author":"B Nieuwenhuis","year":"2023","unstructured":"Nieuwenhuis B, Laperrousaz E, Tribble JR, Verhaagen J, Fawcett JW, Martin KR, Williams PA, Osborne A (2023) Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters. Gene Ther 30(6):503\u2013519. https:\/\/doi.org\/10.1038\/s41434-022-00380-zEpub 2023 Jan 13","journal-title":"Gene Ther"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01663-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01663-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01663-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:20:44Z","timestamp":1700439644000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01663-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01663-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were approved by the Institutional Animal Care and Use Committee of Vanderbilt University Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The funding sources had no involvement in the study design, or collection, analysis, or interpretation of the data. The authors confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}